Top

EJNMMI Research

Published in:

Open Access 01-12-2016 | Short communication

Test-retest analysis of a non-invasive method of quantifying [¹¹C]-PBR28 binding in Alzheimer’s disease

Authors: Akshay Nair, Mattia Veronese, Xiaohui Xu, Charles Curtis, Federico Turkheimer, Robert Howard, Suzanne Reeves

Published in: EJNMMI Research | Issue 1/2016

Abstract

Purpose

In order to maximise the utility of [¹¹C]-PBR28 for use in longitudinal studies and clinical trials in Alzheimer’s disease (AD), there is a need to develop non-invasive metrics of tracer binding that do not require arterial cannulation. Recent work has suggested that standardised uptake value (SUV)-based methods may be sensitive to changes in translocator protein (TSPO) levels associated with neurodegeneration. However, the test-retest reliability of these approaches in AD over a time period relevant for clinical trials is unknown. In this study, the test-retest reliability of three SUV-based metrics was assessed in AD patients over 12 weeks.

Methods

Five patients with mild AD and the high-affinity binding TSPO genotype underwent two [¹¹C]-PBR28 PET scans approximately 12 weeks apart. The test-retest reliability (TRR) of the unadjusted SUV, SUV relative to cerebellar grey matter (SUVR_C) and SUV normalised to whole brain activity (SUVR_WB) in nine cortical and limbic regions of interest was assessed using the absolute variability and the intraclass correlation coefficient.

Results

Of the three measures, SUVR_WB performed best overall, showing low absolute variability (mean −0.13 %, SD 2.47 %) and high reliability (mean ICC = 0.83). Unadjusted SUV also performed well, with high reliability (ICC = 0.94) but also high variability (mean −1.24 %, SD 7.28 %). By comparison, the SUVR_C showed higher variability (mean −3.98 %, SD 7.07 %) and low reliability (ICC = 0.65).

Conclusions

In this AD sample, we found that SUV-derived metrics of [¹¹C]-PBR28 binding showed high stability over 12 weeks. These results compare favourably with studies reporting TRR of absolute quantification of [¹¹C]-PBR28. Pending further validation of SUV-based measures of [¹¹C]-PBR28, semi-quantitative methods of [¹¹C]-PBR28 analysis may prove useful in longitudinal studies of AD.

Available only for authorised users

Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14(7):463–77. doi:10.1038/nri3705.CrossRefPubMed

Chen MK, Guilarte TR. Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair. Pharmacol Ther. 2008;118(1):1–17. doi:10.1016/j.pharmthera.2007.12.004.CrossRefPubMedPubMedCentral

Calsolaro V, Edison P. Neuroinflammation in Alzheimer's disease: Current evidence and future directions. Alzheimers Dement. 2016. doi:10.1016/j.jalz.2016.02.010

Varley J, Brooks DJ, Edison P. Imaging neuroinflammation in Alzheimer’s disease and other dementias: recent advances and future directions. Alzheimers Dement. 2015;11(9):1110–20. doi:10.1016/j.jalz.2014.08.105.CrossRefPubMed

Turkheimer FE, Edison P, Pavese N, Roncaroli F, Anderson AN, Hammers A, et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med. 2007;48(1):158–67.PubMed

Kim S, Nho K, Risacher SL, Inlow M, Swaminathan S, Yoder KK, et al. Gene variation and microglial activity on [C]PBR28 PET in older adults at risk for Alzheimer’s disease. Multimodal Brain Image Anal (2013). 2013;8159:150–8. doi:10.1007/978-3-319-02126-3_15.CrossRef

Zurcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuroimage Clin. 2015;7:409–14. doi:10.1016/j.nicl.2015.01.009.CrossRefPubMedPubMedCentral

Lyoo CH, Ikawa M, Liow JS, Zoghbi SS, Morse CL, Pike VW, et al. Cerebellum can serve as a pseudo-reference region in Alzheimer disease to detect neuroinflammation measured with PET radioligand binding to translocator protein. J Nucl Med. 2015;56(5):701–6. doi:10.2967/jnumed.114.146027.CrossRefPubMedPubMedCentral

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9. doi:10.1016/j.jalz.2011.03.005.CrossRefPubMedPubMedCentral

10.

Molloy DW, Standish TI. A guide to the standardized mini-mental state examination. Int Psychogeriatr. 1997;9 Suppl 1:87–94. discussion 143-50.CrossRefPubMed

11.

Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32(1):1–5. doi:10.1038/jcbfm.2011.147.CrossRefPubMed

12.

Owen DR, Guo Q, Kalk NJ, Colasanti A, Kalogiannopoulou D, Dimber R, et al. Determination of [(11)C]PBR28 binding potential in vivo: a first human TSPO blocking study. J Cereb Blood Flow Metab. 2014;34(6):989–94. doi:10.1038/jcbfm.2014.46.CrossRefPubMedPubMedCentral

13.

Park E, Gallezot JD, Delgadillo A, Liu S, Planeta B, Lin SF, et al. (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. Eur J Nucl Med Mol Imaging. 2015;42(7):1081–92. doi:10.1007/s00259-015-3043-4.CrossRefPubMed

14.

Collste K, Forsberg A, Varrone A, Amini N, Aeinehband S, Yakushev I, et al. Test-retest reproducibility of [(11)C]PBR28 binding to TSPO in healthy control subjects. Eur J Nucl Med Mol Imaging. 2016;43(1):173–83. doi:10.1007/s00259-015-3149-8.CrossRefPubMed

15.

Anderson AN, Pavese N, Edison P, Tai YF, Hammers A, Gerhard A, et al. A systematic comparison of kinetic modelling methods generating parametric maps for [(11)C]-(R)-PK11195. Neuroimage. 2007;36(1):28–37. doi:10.1016/j.neuroimage.2007.02.017.CrossRefPubMed

16.

Turkheimer FE, Rizzo G, Bloomfield PS, Howes O, Zanotti-Fregonara P, Bertoldo A, et al. The methodology of TSPO imaging with positron emission tomography. Biochem Soc Trans. 2015;43(4):586–92. doi:10.1042/BST20150058.CrossRefPubMedPubMedCentral

Title: Test-retest analysis of a non-invasive method of quantifying [11C]-PBR28 binding in Alzheimer’s disease
Authors: Akshay Nair
Mattia Veronese
Xiaohui Xu
Charles Curtis
Federico Turkheimer
Robert Howard
Suzanne Reeves
Publication date: 01-12-2016
Publisher: Springer Berlin Heidelberg
Published in: EJNMMI Research / Issue 1/2016
Electronic ISSN: 2191-219X
DOI: https://doi.org/10.1186/s13550-016-0226-3

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Test-retest analysis of a non-invasive method of quantifying [¹¹C]-PBR28 binding in Alzheimer’s disease

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab

An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET

Optimal 2-[18F]fluoro-2-deoxy-d-galactose PET/CT protocol for detection of hepatocellular carcinoma

Renal PET-imaging with 11C-metformin in a transgenic mouse model for chronic kidney disease

Angiotensin II increases gene expression after selective intra-arterial adenovirus delivery in a rabbit model assessed using in vivo SSTR2-based reporter imaging

Calibration of PET/CT scanners for multicenter studies on differentiated thyroid cancer with 124I